The researchers examined the lifestyle habits, GLP-1 RA usage, and cardiovascular health outcomes of more than 98,000 adults living with T2D and without any prior cardiovascular disease, using data from the Veterans Affairs Million Veteran Program from 2011 to 2023
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide modulate appetite, satiety, and gastric emptying, documented across STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
Retatrutide may be of interest to individuals who: Did not tolerate GLP-1 alone Are exploring metabolic flexibility Are interested in appetite and energy expenditure pathways However, retatrutide remains under clinical investigation and is not broadly FDA-approved for obesity at the time of writing
Resources [1] Kalra A, Yetiskul E, Wehrle CJ, Tuma F
References BECKMAN, K.B